Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)
Bullboard Posts
User Avatar Image
(0)
•••
Comment by PoorOpinionon Jan 30, 2018 5:24pm
83 Views
Post# 27466249

RE:RE:RE:RE:Now we need ...

RE:RE:RE:RE:Now we need ...
Morag44 wrote: So, would you consider averaging up on the achievement of key milestones? Or aside from hiving off the fun money does this remain your position all the way through? Just curious, not an attack. I have a dollar cost average of .13 cents and while I would like to keep all my shares (not nearly as many as you have) I remember the previous results and subsequent price drop. I will move to protect my capital in some way before the report results. Generally speaking, pharma stocks rise on the hype, sell on the news and then depending on the circumstances climb back. The path forward is not always a direct line. Look at the cannabis and block chain stocks for recent can't miss opportunities.


You might be right about rises and falls but this stock is so cheap now that IMO any falls are going to be trivial in comparison to the rises. I agree its been hard to hold this stock since the phase I failure and there's been a number of false starts since then but 2017 genuinely looks like having the possibility of being transformative. Assuming the news flow stays positive that is. Banking profit if it suits your risk appetite is never bad, honestly I think the worst is hindsight investing.

Bullboard Posts
Dealroom for high-potential pre-IPO opportunities